2023-11-08 19:42:49
American health authorities announced on Wednesday that they had approved a highly anticipated drug from the American group Eli Lilly once morest obesity, the latest entrant into a market that has become major for the pharmaceutical industry.
The treatment, which will be marketed under the name Zepbound in the United States, is administered by injection once a week.
The molecule used was already approved once morest diabetes, and sometimes already prescribed outside of official recommendations by certain doctors for weight loss, given its effectiveness.
In a large clinical trial, Zepbound achieved significant weight loss, the US Food and Drug Administration (FDA) said in a statement.
Also read Cholesterol: an enemy of our arteries to be taken seriously
Zepbound is now authorized for people who are obese, or overweight and have a related health problem (type 2 diabetes, high cholesterol, or hypertension).
Its use should be combined with exercise and a low-calorie diet, specifies the FDA.
This drug belongs to a new generation of treatments, mimicking a gastrointestinal hormone (GLP-1) which activates receptors in the brain playing a role in regulating appetite.
Also read Nearly a third more cancers in 15 years
Eli Lilly’s molecule, tirzepatide, was already marketed under the name Mounjaro for people suffering from type 2 diabetes, since FDA authorization in 2022.
The Novo Nordisk laboratory uses a molecule called semaglutide, authorized once morest obesity in the United States since 2021 under the name Wegovy.
Also read Ozempic, the miracle drug that has become a social phenomenon
Its diabetes counterpart, authorized since 2017 and called Ozempic, has recently experienced periodic stock shortages, following causing a furor on social networks for its weight-loss properties.
1699478235
#approves #longawaited #obesity #drug
